Atlas Special Opportunities

Circio Holding ASA is a clinical-stage company dedicated to the development and commercialization of immuno-oncology therapies aimed at treating resistant solid tumors. Its primary product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to selectively infect cancer cells and stimulate the immune system to combat cancer more effectively. In addition to ONCOS-102, Circio's pipeline includes other candidates such as circVec and Mutant KRAS, which are focused on providing targeted immunotherapy solutions for cancer patients. The company's innovative approach seeks to enhance the efficacy of cancer treatments by leveraging the immune response, addressing a critical need in oncology for therapies that can overcome treatment resistance.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing advanced ophthalmic therapies aimed at preserving vision in patients suffering from retinal vascular disorders. Its primary target conditions include diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion, which are significant causes of vision loss worldwide. The company is dedicated to creating innovative treatments that enhance the standard of care for these debilitating eye diseases.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Circio Holding ASA is a clinical-stage company dedicated to the development and commercialization of immuno-oncology therapies aimed at treating resistant solid tumors. Its primary product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to selectively infect cancer cells and stimulate the immune system to combat cancer more effectively. In addition to ONCOS-102, Circio's pipeline includes other candidates such as circVec and Mutant KRAS, which are focused on providing targeted immunotherapy solutions for cancer patients. The company's innovative approach seeks to enhance the efficacy of cancer treatments by leveraging the immune response, addressing a critical need in oncology for therapies that can overcome treatment resistance.

Drone Volt SA is a French company that specializes in the manufacture and sale of professional civilian drones. Established in 2011 and headquartered in Villepinte, France, it operates in several countries, including Belgium, the Netherlands, Canada, Denmark, the United States, Switzerland, and Indonesia. The company provides commercial drones designed for diverse applications such as inspection, surveillance, thermography, and search and rescue operations, catering to sectors like energy, construction, security, and agriculture. In addition to its own drone products, Drone Volt distributes DJI drones and various accessories for civil and commercial use. The company also offers a range of services, including engineering consulting, aerial data acquisition, professional drone training, maintenance, and legal support. It serves government administrations and industrial groups while also engaging in international exports.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.